Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
J Clin Hypertens (Greenwich). 2022 Jun;24(6):750-759. doi: 10.1111/jch.14492. Epub 2022 May 6.
The impact of renin on kidney remain unclear among hypertensives with glucose metabolic disorders (GMD). We aimed to evaluate the association between plasma renin activity (PRA) and kidney damage in hypertensive patients with GMD. Overall, 2033 inpatients with hypertension and GMD free of chronic kidney disease (CKD) at baseline were included. CKD was defined using estimated glomerular filtration rate (eGFR) and urine protein. PRA was treated as continuous variable, and also dichotomized as high (≥0.65) or low (< 0.65) groups. The association of PRA with incident CKD was evaluated using multivariable Cox model controlling for antihypertensive medications and baseline aldosterone, and traditional parameters. Subgroup and interaction analyses were performed to evaluate heterogeneity. During a median follow-up of 31 months, 291 participants developed CKD. The incidence was higher in high-renin group than that in low-renin group (54.6 vs 36.6/1000 person-years). Significant association was observed between PRA and incident CKD, and the association was mainly driven by an increased risk for proteinuria. Each standard deviation increment in log-transformed PRA was associated with 16.7% increased risk of proteinuria (hazard ratio = 1.167, P = .03); compared with low-renin group, there was 78.4% increased risk for high-renin group (hazard ratio = 1.784, P = .001). Nonlinear associations were observed between PRA and kidney damage. Higher PRA is associated with greater risk of incident kidney damage, especially for positive proteinuria, in patients with coexistence of hypertension and diabetes, independent of aldosterone. In this patient population with high risk for kidney damage, PRA may serve as an important predictor.
在伴有糖代谢紊乱(GMD)的高血压患者中,肾素对肾脏的影响尚不清楚。我们旨在评估高血压合并 GMD 患者血浆肾素活性(PRA)与肾脏损害之间的关系。共有 2033 名初诊高血压且无慢性肾脏病(CKD)的患者纳入研究。CKD 采用估算肾小球滤过率(eGFR)和尿蛋白进行定义。PRA 作为连续变量处理,也分为高(≥0.65)或低(<0.65)组。采用多变量 Cox 模型,在控制降压药物和基线醛固酮及传统参数的基础上,评估 PRA 与新发 CKD 的关系。进行亚组和交互作用分析以评估异质性。在中位随访 31 个月期间,291 名参与者发生 CKD。高肾素组的发生率高于低肾素组(54.6 比 36.6/1000 人年)。PRA 与新发 CKD 之间存在显著相关性,这种相关性主要是由蛋白尿风险增加驱动的。log 转化后 PRA 的每标准偏差增加与蛋白尿风险增加 16.7%相关(风险比=1.167,P=0.03);与低肾素组相比,高肾素组的风险增加了 78.4%(风险比=1.784,P=0.001)。PRA 与肾脏损害之间存在非线性关系。在高血压合并糖尿病患者中,较高的 PRA 与更大的新发肾脏损害风险相关,尤其是蛋白尿阳性患者。在这群肾脏损害风险较高的患者中,PRA 可能是一个重要的预测指标。